Health Catalyst (NASDAQ:HCAT) Earns Equal Weight Rating from Stephens

Health Catalyst (NASDAQ:HCAT)‘s stock had its “equal weight” rating reiterated by Stephens in a note issued to investors on Thursday,Benzinga reports. They presently have a $7.00 price objective on the stock. Stephens’ price target indicates a potential upside of 69.00% from the company’s previous close.

A number of other research analysts have also commented on the company. Royal Bank of Canada lowered their target price on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 15th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Piper Sandler dropped their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Wells Fargo & Company reduced their target price on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Finally, Citigroup lowered their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Health Catalyst Stock Down 16.2 %

Shares of NASDAQ:HCAT opened at $4.14 on Thursday. Health Catalyst has a 12 month low of $3.82 and a 12 month high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company’s 50-day moving average price is $6.09 and its two-hundred day moving average price is $7.26. The firm has a market cap of $252.03 million, a P/E ratio of -3.06 and a beta of 1.34.

Insiders Place Their Bets

In other Health Catalyst news, CFO Jason Alger sold 19,599 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.32, for a total transaction of $163,063.68. Following the sale, the chief financial officer now directly owns 86,712 shares in the company, valued at approximately $721,443.84. This trade represents a 18.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total transaction of $34,974.63. Following the completion of the transaction, the insider now owns 85,819 shares of the company’s stock, valued at $465,997.17. This trade represents a 6.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,610 shares of company stock worth $664,043. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harbor Capital Advisors Inc. lifted its holdings in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares in the last quarter. Group One Trading LLC lifted its stake in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after acquiring an additional 2,260 shares in the last quarter. Creative Planning boosted its position in Health Catalyst by 13.2% during the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock worth $174,000 after acquiring an additional 2,486 shares during the last quarter. Two Sigma Securities LLC grew its stake in shares of Health Catalyst by 19.5% during the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock worth $124,000 after acquiring an additional 2,862 shares in the last quarter. Finally, Legato Capital Management LLC raised its holdings in shares of Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after purchasing an additional 3,171 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.